194 related articles for article (PubMed ID: 34982097)
1. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.
Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS
JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
3. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
4. The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease.
Kazi DS; DeJong C; Chen R; Wadhera RK; Tseng CW
J Am Coll Cardiol; 2023 May; 81(21):2103-2111. PubMed ID: 37225364
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
6. Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.
Newman TV; Gabriel N; Liang Q; Drake C; El Khoudary SR; Good CB; Gellad WF; Hernandez I
J Manag Care Spec Pharm; 2022 Feb; 28(2):266-274. PubMed ID: 35098746
[No Abstract] [Full Text] [Related]
7. How does drug treatment for diabetes compare between Medicare Advantage prescription drug plans (MAPDs) and stand-alone prescription drug plans (PDPs)?
Erten MZ; Stuart B; Davidoff AJ; Shoemaker JS; Bryant-Comstock L; Shenolikar R
Health Serv Res; 2013 Jun; 48(3):1057-75. PubMed ID: 23205568
[TBL] [Abstract][Full Text] [Related]
8. Geographic Variation in the Prevalence of High-Risk Medication Use Among Medicare Part D Beneficiaries by Hospital Referral Region.
Chinthammit C; Bhattacharjee S; Axon DR; Slack M; Bentley JP; Warholak TL; Wilson DL; Lo-Ciganic WH
J Manag Care Spec Pharm; 2020 Oct; 26(10):1309-1316. PubMed ID: 32996396
[TBL] [Abstract][Full Text] [Related]
9. Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017.
Liu P; Dhruva SS; Shah ND; Ross JS
Am J Manag Care; 2020 Mar; 26(3):112-117. PubMed ID: 32181626
[TBL] [Abstract][Full Text] [Related]
10. Variability of COPD inhaler coverage in Medicare Part D.
Wormser B; Socal MP; Anderson G
Am J Manag Care; 2021 May; 27(5):187-193. PubMed ID: 34002960
[TBL] [Abstract][Full Text] [Related]
11. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
12. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
13. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
Jung K; McBean AM; Kim JA
J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
[TBL] [Abstract][Full Text] [Related]
14. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
15. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
16. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
18. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
[TBL] [Abstract][Full Text] [Related]
19. Effects of an out-of-pocket maximum in Medicare Part D.
Parasrampuria S; Anderson GF
Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
[TBL] [Abstract][Full Text] [Related]
20. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
